The beauty industry is deploying AI across various parts of its value chain, with recent partnerships seeing the tech used for both product discovery and product creation. 

A peer-reviewed study published in Frontiers in Veterinary Science has found that domestic cats accepted a diet containing cultivated hamster cell biomass at least as well as one based on conventional chicken breast, with the cultivated meat diet actually generating fewer leftovers despite containing significantly less palatability enhancer.

Cultivated protein company Parima has completed the core safety risk assessment stage of Food Standards Australia New Zealand’s (FSANZ) novel food approval process for cultivated meat, becoming the first company outside Australia and New Zealand to reach this point in the FSANZ pathway, and only the second company globally to do so.

Disproquima has acquired Polish cosmetic ingredients distributor Enzym as part of its personal care expansion strategy. The raw materials and ingredients company says that the move represents a “significant milestone” in its Central European growth plan and will enable it to serve customers with greater proximity, technical know-how, and agility.

Indian beauty brand Astrea Beauty has announced it is debuting in the US. The brand blends modern clean beauty principles with ancient Siddha medicine, one of the world’s oldest healing traditions originating in South India. 

A German organic vegetable farm near Lake Constance has unveiled a new digital marketing platform designed to connect biocyclic vegan producers with processors, retailers, and consumers, as interest in livestock-free agricultural production continues to grow within the organic sector.

Researchers at Columbia University Irving Medical Center have identified a gene that drives the development of neuroendocrine prostate cancer (NEPC), an aggressive form of the disease. Their study showed that genetic or pharmacological inhibition of Sirtuin 1 prevents the growth of NEPC tumors in mice, laying the groundwork for future clinical studies aimed at developing new treatments for NEPC in humans.